ESMO 2019: The NABUCCO Study, Pre-operative Ipilimumab and Nivolumab in Locoregionally Advanced, Stage III, Urothelial Cancer

ESMO 2019 NABUCCO study, ABACUS study, PURE-01, neoadjuvant ipilimumab and nivolumab,

Read the full article here

Related Articles